Revised forecast
Fiscal year ending March 2027 · Six months and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In the pharmaceutical business, the company expects growth from Deramiocel, the new product portfolio and royalty income associated with overseas sales of Uptravi. In the functional foods business, it expects higher revenue from developing and launching new products and strengthening initiatives for priority products.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → Cumulative second-quarter results 95,000 / Full year 200,000（Cumulative second-quarter results 19.3% / Full year 17.1%） |
| Operating profit | Not disclosed → Cumulative second-quarter results 17,500 / Full year 38,000（Cumulative second-quarter results △10.6% / Full year 7.1%） |
| Profit attributable to owners of the parent | Not disclosed → Cumulative second-quarter results 14,000 / Full year 30,300（Cumulative second-quarter results △11.2% / Full year 1.9%） |
| Net income per share | Not disclosed → Cumulative second-quarter results 207.71 / Full year 449.55 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months and full year |
| Previous-period results | Full year: revenue ¥170,771 million, operating profit ¥35,496 million, profit before tax ¥36,462 million, profit attributable to owners of the parent ¥29,721 million, basic earnings per share ¥441.00 |
| Reason for the revision | In the pharmaceutical business, the company expects growth from Deramiocel, the new product portfolio and royalty income associated with overseas sales of Uptravi. In the functional foods business, it expects higher revenue from developing and launching new products and strengthening initiatives for priority products. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmaceutical business, the company expects growth from the new product portfolio, including Deramiocel, Erleada, Fintepla and Uptravi, which are scheduled for launch in the United States, as well as royalty income associated with overseas sales of Uptravi. In the functional foods business, the company expects higher revenue from developing and launching new products and strengthening initiatives for priority products.